GeneralBullishBlockonomi · 3h ago6/10
📰
Inhibrx Biosciences (INBX) Stock Soars 17% Following Impressive Phase 2 Cancer Data
Inhibrx Biosciences (INBX) stock surged 17% following positive Phase 2 clinical trial results showing that INBRX-106 combination therapy doubled response rates in head and neck cancer patients, demonstrating meaningful therapeutic efficacy.